Drug Profile


Alternative Names: ASONEP; iSONEP; LT-1009; Sonepcizumab/LT1009; Sphingomab™

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Lpath
  • Developer Lpath; Pfizer
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Preclinical Diabetic retinopathy; Eye disorders; Inflammation; Multiple sclerosis
  • Discontinued Heart failure; Renal cell carcinoma

Most Recent Events

  • 22 Mar 2016 Sonepcizumab is no longer licensed to Pfizer in USA(Lpath, Form 10-K, March 2016)
  • 30 Sep 2015 Discontinued - Phase-II for Renal cell carcinoma (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 21 Jul 2015 Sonepcizumab is still in phase II trials for Wet age-related macular degeneration in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top